302
Participants
Start Date
March 2, 2016
Primary Completion Date
July 10, 2017
Study Completion Date
July 10, 2017
REGN910-3
Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
Intravitreal Aflibercept Injection (IAI)
Mesa
Tucson
Arcadia
Beverly Hills
Mountain View
Oceanside
Palm Desert
Colorado Springs
New London
Lakeland
Tampa
Winter Haven
Augusta
Decatur
‘Aiea
Chicago
New Albany
Shawnee Mission
Lexington
Portland
Baltimore
Rockville
Boston
Grand Rapids
Jackson
Minneapolis
Florissant
Las Vegas
Bloomfield
Edison
Teaneck
Albany
Rochester
Asheville
Charlotte
Kingston
Florence
West Columbia
Rapid City
Germantown
Nashville
Abilene
Austin
Dallas
Fort Worth
Harlingen
Houston
San Antonio
The Woodlands
Willow Park
Bellevue
Collaborators (1)
Bayer
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY